Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau

Research output: Contribution to journalJournal article – Annual report year: 2017Researchpeer-review

Documents

DOI

  • Author: Do, Vu An

    Statens Serum Institut, Denmark

  • Author: Biering-Sorensen, Sofie

    Statens Serum Institut, Denmark

  • Author: Fisker, Ane Bærent

    Statens Serum Institut, Denmark

  • Author: Balé, Carlito

    INDEPTH Network, Guinea-Bissau

  • Author: Rasmussen, Stine Møller

    Statens Serum Institut, Denmark

  • Author: Christensen, Lone Damkjær

    Statens Serum Institut, Denmark

  • Author: Jensen, Kristoffer Jarlov

    Adaptive Immunology, Division of Immunology & Vaccinology, National Veterinary Institute, Technical University of Denmark, Kemitorvet, 2800, Kgs. Lyngby, Denmark

  • Author: Martins, Cesário

    INDEPTH Network, Guinea-Bissau

  • Author: Aaby, Peter

    INDEPTH Network, Guinea-Bissau

  • Author: Benn, Christine Stabell

    Statens Serum Institut, Denmark

View graph of relations

Background: Children in Guinea-Bissau receive measles vaccine (MV) at 9 months of age, but studies have shown that an additional dose before 9 months of age might have beneficial nonspecific effects. Within a randomized trial designed to examine nonspecific effects of early MV receipt on mortality, we conducted a substudy to investigate the effect of early MV receipt on morbidity. Methods: Children were randomly assigned at a ratio of 2: 1 to receive 2 doses of MVat 18 weeks and age 9 months (intervention group) or 1 dose of MV at age 9 months, in accordance with current practice (control group). Children were visited weekly from enrollment to age 9 months; the mother reported morbidity, and the field assistants examined the children. Using Cox and binomial regression models, we compared the 2 randomization groups. Results: Among the 1592 children, early measles vaccination was not associated with a higher risk of the well-known adverse events of fever, rash, and convulsions within the first 14 days. From 15 days after randomization to age 9 months, early measles vaccination was associated with reductions in maternally reported diarrhea (hazard ratio [HR], 0.89; 95% confidence interval [CI],.82-. 97), vomiting (HR, 0.86; 95% CI,.75-. 98), and fever (HR, 0.93; 95% CI,.87-1.00).Conclusion. Early MV receipt was associated with reduced general morbidity in the following months, supporting that early MV receipt may improve the general health of children.
Original languageEnglish
JournalJournal of Infectious Diseases
Volume215
Issue number8
Pages (from-to)1188-1196
ISSN0022-1899
DOIs
Publication statusPublished - 2017

Bibliographical note

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence.

CitationsWeb of Science® Times Cited: No match on DOI

    Research areas

  • Measles vaccine, Adverse events, Morbidity, Non-specific effects of vaccines, Heterologous immunity, Pediatric

Download statistics

No data available

ID: 132820639